ArticleIntensive care medicine experimental2022
High levels of monocytic myeloid-derived suppressor cells are associated with favorable outcome in patients with pneumonia and sepsis with multi-organ failure.
Article in Intensive care medicine experimental, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19.Science advances · 2023Trial
- Myeloid-Derived Suppressor Cells in Sepsis: Pathophysiology, Duality, and Therapeutic Frontiers.Shock (Augusta, Ga.) · 2026Review
- Myeloid-derived suppressor cells in sepsis: drivers of persistent immunosuppression and targets for precision immunotherapy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Prostate Cancer: Dissecting Novel Immunosuppressive Mechanisms Through Context-Specific Transcriptomic Programs and MDSC Cells.International journal of molecular sciences · 2026Article
- RhIL-11 reverses liver damage in septic mice by STAT3-mediated M-MDSCs induction modulated by a parallel mTORC1 signaling branch.Journal of inflammation (London, England) · 2025Article
- Prognostic value of multivariate logistic regression analysis and amyloid A lactate monitoring in patients with severe pneumonia-associated sepsis.BMC pulmonary medicine · 2025Article
- A Pilot Study Assessing the Utility of Quantitative Myeloid-Derived Suppressor Cell Measurements in Detecting Posttraumatic Infection.Critical care explorations · 2025Observational
- Pharmacological and genetic inhibition of ARG2 in CXCR2Theranostics · 2025Article
- Using weight loss to predict outcome and define a humane endpoint in preclinical sepsis studies.Scientific reports · 2024Article
- Monocytic myeloid-derived suppressor cells as an immune indicator of early diagnosis and prognosis in patients with sepsis.BMC infectious diseases · 2024Article
- Article
- Review
- Immunomodulatory actions of myeloid-derived suppressor cells in the context of innate immunity.Innate immunity · 2024Review
- Here, There, and Everywhere: Myeloid-Derived Suppressor Cells in Immunology.Journal of immunology (Baltimore, Md. : 1950) · 2023Review
- Deciphering the roles of myeloid derived suppressor cells in viral oncogenesis.Frontiers in immunology · 2023Review
- The immunological function of CXCR2 in the liver during sepsis.Journal of inflammation (London, England) · 2022Review
- Modes of action and diagnostic value of miRNAs in sepsis.Frontiers in immunology · 2022Review
- Integrated machine learning approaches for flow cytometric quantification of myeloid-derived suppressor cells in acute sepsis.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundMyeloid-derived suppressor cells (MDSCs) are immature myeloid cells with immunosuppressive functions sub-classified into monocytic and polymorphonuclear MDSCs (M-MDSCs and PMN-MDSCs). Clinical studies reported increased levels of MDSCs that were associated with poor outcome in sepsis patients. Since sepsis patients exhibit signs of inflammation and immunosuppression, MDSCs may provide benefit by dampening deleterious inflammation in some patients. To test this hypothesis, we measured MDSCs in critically ill sepsis patients with pneumonia and multi-organ dysfunctions and a high likelihood of death.
methodsThis was a prospective multicenter observational cohort study performed in eight ICUs in Athens and Thessaloniki, Greece, enrolling critically ill patients with pneumonia and sepsis with multi-organ dysfunctions. A flow cytometry approach using blood collected at study inclusion in tubes containing lyophilized antibodies combined to unsupervised clustering was developed to quantify M-MDSCs and PMN-MDSCs.
resultsForty-eight patients were included, of whom 34 died within 90 days. At study inclusion, M-MDSCs and PMN-MDSCs were increased in sepsis patients when compared to healthy subjects (3.07% vs 0.96% and 22% vs 2.1% of leukocytes, respectively; p < 10
conclusionThis is the first study to associate high levels of M-MDSCs with improved survival in sepsis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.